Bicycle Therapeutics (FRA:50BA) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:50BA Bicycle Therapeutics PLC FRA:50BA
56 GF Score
Price €3.50
GF Value €11.43
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Bicycle Therapeutics FFO per Share?

FFO per Share only applies to REITs.

FRA:50BA
56GF Score
Bicycle Therapeutics PLC FRA:50BA
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bicycle Therapeutics (FRA:50BA) Overvalued in 2026?

Based on GuruFocus' analysis, Bicycle Therapeutics stock appears to be undervalued. The current stock price of €3.50 is trading 69.4% below its estimated GF Value™ of €11.43. GuruFocus considers Bicycle Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:50BA:

  • FFO per Share:
  • GF Value™: €11.43 vs. price of €3.50 (69.4% below fair value)
  • GF Score™: 56/100 with 5 warning signs

No single metric tells the full story. See the FRA:50BA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bicycle Therapeutics Business Description

Other Exchanges BCYC:USA50BA:Germany
Address Granta Park, Great Abington, Blocks A and B, Portway Building, Cambridge, GBR, CB21 6GS
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
56GF Score

Get the complete analysis for FRA:50BA

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.50
Price
€11.43
GF Value